Vancomycin disposition following intraperitoneal administration in children receiving peritoneal dialysis

被引:2
|
作者
Blowey, Douglas L.
Warady, Bradley A.
Abdel-Rahman, Susan
Frye, Reginald F.
Manley, Harold J.
机构
[1] Univ Missouri, Childrens Mercy Hosp & Clin, Dept Pediat Nephrol, Kansas City, MO 64110 USA
[2] Univ Missouri, Childrens Mercy Hosp & Clin, Dept Clin Pharmacol, Kansas City, MO 64110 USA
[3] Univ Florida, Dept Pharm Practice, Gainesville, FL USA
[4] Albany Coll Pharm, Albany, NY USA
来源
PERITONEAL DIALYSIS INTERNATIONAL | 2007年 / 27卷 / 01期
关键词
vancomycin; pharmacokinetics; pediatric;
D O I
暂无
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background. Little information is available on the disposition of vancomycin during chronic peritoneal dialysis (PD) in children. The primary objective of this study was to investigate the disposition of vancomycin following intraperitoneal (IP) administration in children receiving short-dwelt [e.g., automated PD (APD)] and Long-dwell [e.g., continuous ambulatory PD (CAPD)] PD. Methods: A 6-hour exchange containing vancomycin 500 mg/L, using an exchange volume of 1100 mL/m(2) body surface area (BSA), was followed by 4-, 6-, and 8-hour antibiotic-free exchanges. The 8-hour exchange was followed by three to four 90-minute antibiotic-free exchanges. Serial blood and dialysis effluent samples were obtained and analyzed for vancomycin concentration by high-pressure Liquid chromatography. Pharmacokinetic parameters were computed using noncompartmentat methods. Results: The bioavaiiability of vancomycin during a 6-hour IP exchange was 70% +/- 5%, resulting in a delivered dose of 12.0 +/- 1.8 mg/kg, and a 6-hour serum vancomycin concentration of 23.3 +/- 7.2 mu g/mL. Total body vancomycin clearance measured 10.72 +/- 4.52 mL/minute/1.73 m(2) BSA, while clearance attributable to PD measured 2.78 +/- 1.08 mL/min/1.73 m(2) BSA and accounted for 29% +/- 11% of total vancomycin clearance. Dialysis clearance during long-dwell (CAPD) and short-dwell (APD) regimens was similar, measuring 2.46 +/- 1.04 and 3.09 +/- 1.28 mL/min/1.73 m(2) BSA, accounting for 25% +/- 13% and 32% +/- 12% of total body clearance respectively. Conclusions: Intraperitoneal absorption and dialysis clearance of vancomycin in children receiving PD are similar to those reported in adult dialysis patients. In contrast, total body clearance of vancomycin appears to be increased and the elimination half-Life decreased in children, due to increased elimination by non-renal nondialysis routes. For intermittent IP vancomycin therapy in children with peri-tonitis, an IP load containing vancomycin 1000 mg/L (or 30 mg/kg), followed a single full-fill (1100 mL/m(2) BSA) daily exchange, containing vancomycin 250 mg/L (or 7.5 mg/kg), from day 2 until the end of treatment will maintain a vancomycin dialysate concentration of > 4 mu g/mL.
引用
收藏
页码:79 / 85
页数:7
相关论文
共 50 条
  • [1] Vancomycin absorption after intraperitoneal administration in children receiving peritoneal dialysis.
    Blowey, DL
    Warady, BA
    Manley, HJ
    Frye, RF
    Smith, C
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (02) : P37 - P37
  • [2] Disposition of ceftazidime after intraperitoneal administration in adolescent patients receiving continuous cycling peritoneal dialysis
    Sisterhen, LL
    Stowe, CD
    Farrar, HC
    Blaszak, CK
    Blaszak, RT
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2006, 47 (03) : 503 - 508
  • [3] Disposition and bioavailability of ceftazidime after intraperitoneal administration in patients receiving continuous ambulatory peritoneal dialysis
    Stea, S
    Bachelor, T
    Cooper, M
    deSouza, P
    Koenig, K
    Bolton, WK
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1996, 7 (11): : 2399 - 2402
  • [4] Pharmacokinetics of vancomycin in children receiving peritoneal dialysis.
    Blowey, DL
    Warady, BA
    Manley, HJ
    Frye, RF
    Smith, C
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (02) : P38 - P38
  • [5] INTRAPERITONEAL ADMINISTRATION OF ACYCLOVIR IN PATIENTS RECEIVING CONTINUOUS AMBULATORY PERITONEAL-DIALYSIS
    BURGESS, ED
    GILL, MJ
    JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 30 (11): : 997 - 1000
  • [6] Intraperitoneal pharmacokinetics of vancomycin in patients on automated peritoneal dialysis
    Lam, Edwin
    Lien, Yi Ting Kayla
    Kraft, Walter K.
    Stickle, Douglas F.
    Piraino, Beth
    Zhang, Jingjing
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2022, 15 (03): : 649 - 657
  • [7] Pharmacokinetics of Intraperitoneal Vancomycin in Patients on Automated Peritoneal Dialysis
    Lam, Edwin
    Kraft, Walter K.
    Stickle, Douglas F.
    Piraino, Beth M.
    Zhang, JingJing
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (10): : 336 - 336
  • [8] Increase of the bioavailability of intraperitoneal erythropoietin in children on peritoneal dialysis by administration in small dialysis bags
    Reddingius, RE
    deBoer, AW
    Schroder, CH
    Willems, JL
    Monnens, LAH
    PERITONEAL DIALYSIS INTERNATIONAL, 1997, 17 (05): : 467 - 470
  • [9] Infectious outcomes following gastrostomy in children receiving peritoneal dialysis
    Chanel Prestidge
    Jane Ronaldson
    William Wong
    Maria Stack
    Tonya Kara
    Pediatric Nephrology, 2015, 30 : 849 - 854
  • [10] Infectious outcomes following gastrostomy in children receiving peritoneal dialysis
    Prestidge, Chanel
    Ronaldson, Jane
    Wong, William
    Stack, Maria
    Kara, Tonya
    PEDIATRIC NEPHROLOGY, 2015, 30 (05) : 849 - 854